CERo Therapeutics

(OTC) CERO

Current Price$0.02

Market Cap$953.00K

Since IPO (2021)-100%

5 YearN/A

1 Year-100%

1 Month-34%

CERo Therapeutics Financials at a Glance

Market Cap

$953.00K

Revenue (TTM)

$0.00

Net Income (TTM)

-$20.70M

EPS (TTM)

-$73.30

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.02

Volume

396,217

Open

$0.02

Price

$0.02

Volume

396,217

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.02 - $26.99

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.02

Volume

396,217

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.02 - $26.99

CERO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CERo Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Christopher B. Ehrlich, MBA

Website

www.cero.bio

Headquarters

South San Francisco, CA 94080, US

CERO Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

Return on Assets

-9%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$953.00K

Shares Outstanding

45.11M

Volume

396.22K

Avg. Volume

523.12K

Financials (TTM)

Gross Profit

-$1.09M

Operating Income

-$18.46M

EBITDA

-$17.38M

Operating Cash Flow

-$16.08M

Capital Expenditure

$0.00

Free Cash Flow

-$16.08M

Cash & ST Invst.

$1.66M

Total Debt

$699.11K

CERo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$276.14K

-2.5%

Gross Margin

0.00%

N/A

Market Cap

$953.00K

N/A

Market Cap/Employee

$119.13K

N/A

Employees

N/A

Net Income

-$5.89M

-15.3%

EBITDA

-$4.85M

-0.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$259.14K

-93.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$136.77K

-70.4%

Short Term Debt

$461.58K

-74.5%

Return on Assets

-9.39%

N/A

Return on Invested Capital

2.01%

N/A

Free Cash Flow

-$2.76M

+37.9%

Operating Cash Flow

-$2.76M

+37.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PTIXProtagenic Therapeutics, Inc.

PTIXProtagenic Therapeutics, Inc.$0.52-15.70%

XRTXXORTX Therapeutics Inc.

XRTXXORTX Therapeutics Inc.$2.30-4.17%

BCTXZBriaCell Therapeutics Corp. Warrant

BCTXZBriaCell Therapeutics Corp. Warrant$0.08+0.00%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$1.80+3.76%

GLMDGalmed Pharmaceuticals Ltd.

GLMDGalmed Pharmaceuticals Ltd.$0.67+8.08%

LIMNLiminatus Pharma, Inc. Class A Common Stock

LIMNLiminatus Pharma, Inc. Class A Common Stock$0.18-1.94%

MLECMoolec Science S.A.

MLECMoolec Science S.A.$7.30+0.69%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

IUSBiShares Trust - iShares Core Universal Usd Bond ETF

IUSBiShares Trust - iShares Core Universal Usd Bond ETF$46.15+0.00%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.49-0.02%

ATPCAgape Atp

ATPCAgape Atp$6.35+1.23%

IALTBlackrock ETF Trust - iShares Systematic Alternatives Active ETF

IALTBlackrock ETF Trust - iShares Systematic Alternatives Active ETF$28.24+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.45+0.01%

SIDUSidus Space

SIDUSidus Space$5.26-0.14%

OPENOpendoor Technologies

OPENOpendoor Technologies$5.19+0.09%

Questions About CERO

What is the current price of CERo Therapeutics?

CERo Therapeutics is trading at $0.02 per share.

What is the 52-week range for CERo Therapeutics?

Over the past 52 weeks, CERo Therapeutics has traded between $0.02 and $26.99.

How much debt does CERo Therapeutics have?

As of the most recent reporting period, CERo Therapeutics reported total debt of $598.35K.

How much cash does CERo Therapeutics have on hand?

CERo Therapeutics reported $857.49K in cash and cash equivalents in its most recent financial results.

What is CERo Therapeutics’s dividend yield?

CERo Therapeutics does not currently have a dividend yield.

CERo Therapeutics

CERo Therapeutics Financials at a Glance

CERO News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About CERo Therapeutics

CERO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

CERo Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CERO

What is the current price of CERo Therapeutics?

What is the 52-week range for CERo Therapeutics?

How much debt does CERo Therapeutics have?

How much cash does CERo Therapeutics have on hand?

What is CERo Therapeutics’s dividend yield?

Premium Investing Services